Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Insulin lispro:a new quick-acting insulin analogue

Insulin lispro:a new quick-acting insulin analogue Insulin lispro (Humalog®) is a biosynthetic insulin analogue in which the positions of proline and lysine are reversed in the C-terminal portion of the B chain. Human insulin readily self-associates into hexamers, which dissociate relatively slowly following subcutaneous injection. In consequence, there is a clinically important delay between the subcutaneous injection of soluble insulin and its maximal pharmacodynamic effect. The clinical development of lispro has been based on minor and elegant manipulation of the amino acid sequence to create an insulin which self associates poorly, and is therefore absorbed more rapidly into the circulation. By virtue of this characteristic, it has a more rapid onset of action than soluble insulin preparations, and a shorter duration of action. Potential clinical benefits include better matching of peak insulin action to food absorption following meals, and better glycaemic control in the immediate post-prandial period together with less risk of hypoglycaemia in the period before the next meal is due. An important practical advantage for patients is that the insulin injection does not have to be taken 30 min before meals, as recommended for soluble insulin, but can instead be given almost immediately before meals. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Expert Opinion on Investigational Drugs Taylor & Francis

Insulin lispro:a new quick-acting insulin analogue

Gale, Edwin AM
Expert Opinion on Investigational Drugs , Volume 6 (9): 10 – Sep 1, 1997
Download PDF
10 pages

Loading next page...
 
/lp/taylor-francis/insulin-lispro-a-new-quick-acting-insulin-analogue-YQgJdaPryw

References (16)

Publisher
Taylor & Francis
Copyright
© 1997 Ashley Publications Ltd.
ISSN
1744-7658
eISSN
1354-3784
DOI
10.1517/13543784.6.9.1247
Publisher site
See Article on Publisher Site

Abstract

Insulin lispro (Humalog®) is a biosynthetic insulin analogue in which the positions of proline and lysine are reversed in the C-terminal portion of the B chain. Human insulin readily self-associates into hexamers, which dissociate relatively slowly following subcutaneous injection. In consequence, there is a clinically important delay between the subcutaneous injection of soluble insulin and its maximal pharmacodynamic effect. The clinical development of lispro has been based on minor and elegant manipulation of the amino acid sequence to create an insulin which self associates poorly, and is therefore absorbed more rapidly into the circulation. By virtue of this characteristic, it has a more rapid onset of action than soluble insulin preparations, and a shorter duration of action. Potential clinical benefits include better matching of peak insulin action to food absorption following meals, and better glycaemic control in the immediate post-prandial period together with less risk of hypoglycaemia in the period before the next meal is due. An important practical advantage for patients is that the insulin injection does not have to be taken 30 min before meals, as recommended for soluble insulin, but can instead be given almost immediately before meals.

Journal

Expert Opinion on Investigational Drugs – Taylor & Francis

Published: Sep 1, 1997

There are no references for this article.